MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Jazz Pharmaceuticals plc - Company Profile (NASDAQ:JAZZ)

Consensus Ratings for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ) (?)
Ratings Breakdown: 1 Hold Rating(s), 13 Buy Rating(s)
Consensus Rating:Buy (Score: 2.93)
Consensus Price Target: $188.73 (37.69% upside)

Analysts' Ratings History for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)
Show:
DateFirmActionRatingPrice TargetActions
6/28/2016BMO Capital MarketsInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/21/2016MizuhoReiterated RatingBuy$193.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/18/2016Wells FargoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016Leerink SwannReiterated RatingOutperform$200.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Piper JaffrayReiterated RatingOverweight$186.00 -> $188.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Goldman SachsInitiated CoverageNeutral -> Buy$196.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Deutsche BankReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016SunTrustReiterated RatingBuy$200.00 -> $210.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/5/2016Canaccord GenuityReiterated RatingBuy$170.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2016Northland SecuritiesReiterated RatingOutperform$175.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/19/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016Stifel NicolausLower Price TargetBuy$225.00 -> $200.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/25/2015Sanford C. BernsteinInitiated CoverageMarket Perform$160.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2015GuggenheimBoost Price TargetBuy$210.00 -> $220.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/11/2015Cantor FitzgeraldSet Price TargetBuy -> Hold$175.00 -> $165.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/27/2015Citigroup Inc.Initiated CoverageBuy$195.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2014R. F. LaffertyUpgradeNeutral -> Buy$200.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/19/2014S&P Equity ResearchInitiated CoverageHold -> Average$43.66 -> $42.19View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/6/2014FBR & Co.Lower Price Target$214.00 -> $213.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/23/2014Buckingham ResearchInitiated CoverageBuy$215.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/10/2016Q1$2.31$2.26$338.86 million$336.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q415$2.60$2.60$349.98 million$340.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315$2.56$2.52$348.15 million$340.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215$2.41$2.41$335.58 million$333.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115$2.15$1.99$309.50 million$309.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q414$2.30$2.44$319.74 million$328.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q314$2.23$2.33$302.90 million$306.58 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014Q214$1.92$2.05$273.39 million$291.23 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114$1.79$1.61$254.86 million$247.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2014Q413$1.78$1.72$238.12 million$235.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313$1.67$1.78$227.38 million$232.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q2 2013$1.52$1.43$208.71 million$208.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q1 2013$1.35$1.37$189.92 million$196.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2013Q4 2012$1.41$1.53$183.80 million$183.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312$1.31$1.29$178.57 million$175.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2012$1.05$1.09ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2012$0.90$0.91ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2011$0.89$0.94ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011$0.67$0.82ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2011$0.57$0.59ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2011$0.60$0.63ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$1.39$1.48$1.44
Q2 20163$1.87$2.15$1.99
Q3 20164$1.88$2.16$2.01
Q4 20164$1.95$2.70$2.37
(Data provided by Zacks Investment Research)
Dividend History for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/15/2016Michael Patrick MillerSVPSell100$149.64$14,964.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2016Karen L SmithCMOBuy557$149.61$83,332.77View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Heather Ann McsharryDirectorSell697$145.20$101,204.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Michael Patrick MillerSVPSell100$145.20$14,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/25/2016Karen J WilsonSVPSell604$160.00$96,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2016Michael Patrick MillerSVPSell100$145.79$14,579.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/13/2016Karen J WilsonSVPSell5,007$150.00$751,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/12/2016Russell J CoxCOOSell4,000$136.98$547,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2016Karen J WilsonSVPSell2,161$140.90$304,484.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Michael Patrick MillerSVPSell100$129.17$12,917.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/8/2016Bruce C CozaddCEOSell2,500$126.04$315,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/29/2016Paul TreacySVPSell354$123.48$43,711.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2016Seamus MulliganDirectorSell27,968$122.71$3,431,953.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/16/2016Michael Patrick MillerSVPSell100$115.63$11,563.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2016Patrick G EnrightDirectorSell10,000$117.92$1,179,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/9/2016Bruce C CozaddCEOSell2,500$111.37$278,425.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Michael Patrick MillerSVPSell100$122.66$12,266.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2016Bruce C CozaddCEOSell2,500$123.81$309,525.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2016Patrick G EnrightDirectorSell10,000$138.09$1,380,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Michael Patrick MillerSVPSell100$136.99$13,699.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2015Bruce C CozaddCEOSell2,500$139.72$349,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2015Patrick G EnrightDirectorSell10,424$146.67$1,528,888.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/23/2015Seamus MulliganDirectorSell27,968$145.86$4,079,412.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2015Bruce C CozaddCEOSell2,500$128.53$321,325.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2015Patrick G EnrightDirectorSell10,000$135.29$1,352,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2015Suzanne Sawochka HooperEVPSell2,000$125.00$250,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/13/2015Bruce C CozaddCEOSell2,500$131.50$328,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Patrick G EnrightDirectorSell10,000$133.79$1,337,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2015Michael Patrick MillerSVPSell100$145.23$14,523.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Bruce C. CozaddCEOSell2,500$163.07$407,675.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Patrick G EnrightDirectorSell10,000$165.99$1,659,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2015Bruce C CozaddCEOSell5,000$177.79$888,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2015Suzanne Sawochka HooperEVPSell4,000$177.79$711,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Patrick G EnrightDirectorSell10,000$177.11$1,771,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2015Bruce C CozaddCEOSell5,000$173.16$865,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2015Suzanne Sawochka HooperEVPSell4,000$173.16$692,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2015Karen J WilsonSVPSell5,751$179.59$1,032,822.09View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Karen J WilsonSVPSell5,494$179.57$986,557.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2015Bruce C CozaddCEOSell5,000$181.45$907,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2015Suzanne Sawochka HooperEVPSell4,000$181.45$725,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2015Seamus MulliganDirectorSell50,000$174.59$8,729,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Patrick G EnrightDirectorSell10,000$160.25$1,602,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2014Seamus MulliganDirectorSell50,000$163.40$8,170,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2014Patrick G EnrightDirectorSell2,343$170.98$400,606.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2014Bruce C CozaddCEOSell5,000$178.79$893,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2014Suzanne Sawochka HooperEVPSell1,852$178.79$331,119.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Patrick G EnrightDirectorSell10,000$172.74$1,727,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Jeffrey K TobiasCMOSell4,598$170.12$782,211.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2014Iain McgillSVPSell7,066$172.03$1,215,563.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014Jeffrey K TobiasCMOSell1,000$154.04$154,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2014Patrick G EnrightDirectorSell10,000$160.56$1,605,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2014Seamus MulliganDirectorSell50,000$163.16$8,158,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2014Seamus MulliganDirectorSell35,294$163.70$5,777,627.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014Jeffrey K TobiasCMOSell1,000$171.22$171,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2014Karen J WilsonSVPSell3,000$175.00$525,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2014Seamus MulliganDirectorSell50,000$175.00$8,750,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2014Bruce C CozaddCEOSell5,000$170.32$851,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014Karen J WilsonSVPSell2,500$170.00$425,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014Suzanne Sawochka HooperEVPSell1,852$168.00$311,136.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Bruce C CozaddCEOSell5,000$133.15$665,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Suzanne Sawochka HooperEVPSell1,185$133.15$157,782.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014Jeffrey K TobiasCMOSell4,933$135.42$668,026.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2014Bruce C CozaddCEOSell5,000$155.00$775,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2014Suzanne Sawochka HooperEVPSell1,853$155.00$287,215.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2014Karen J WilsonSVPSell2,500$165.00$412,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2014Seamus MulliganDirectorSell50,000$149.69$7,484,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2014Russell J CoxCOOSell2,000$155.00$310,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2014Fintan KeeganEVPSell3,750$150.00$562,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2014Bruce C CozaddCEOSell5,000$142.34$711,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Jeffrey TobiasCMOSell1,000$128.01$128,010.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014Bruce CozaddCEOSell5,000$128.92$644,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/17/2014Rick WinninghamDirectorSell27,500$140.00$3,850,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2014Jeffrey TobiasCMOSell3,000$128.54$385,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2014Bruce CozaddCEOSell5,000$123.18$615,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2014Jeffrey TobiasCMOSell3,000$152.99$458,970.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2014Fintan KeeganEVPSell4,640$159.90$741,936.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2014Seamus MulliganDirectorSell550,000$156.25$85,937,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014Patrick EnrightDirectorSell559,628$152.39$85,281,710.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)
DateHeadline
06/28/16 04:41 PMStrong Sell Calls Recommendations For Jazz Pharmaceuticals plc (NASDAQ:JAZZ) At 0 - Investor Newswire
06/27/16 04:42 PMJazz Pharmaceuticals plc (NASDAQ:JAZZ) Earnings Glance and Target Price Review - Engelwood Daily
06/27/16 04:42 PMJazz Pharmaceuticals Plc Ireland (NASDAQ:JAZZ) Short Interest Increased By 45.33% - Press Telegraph
06/27/16 04:42 PMToday's Hot List: Southwestern Energy Company (NYSE:SWN), Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ ... - KC Register
06/27/16 04:42 PMJazz Pharmaceuticals Plc (NASDAQ:JAZZ) Broker Price Targets For The Coming Week - Fiscal Standard
06/27/16 04:42 PMJazz Pharmaceuticals Announces Expiration of HSR Waiting Period for Proposed Celator Pharmaceuticals, Inc ... - PR Newswire (press release)
06/27/16 09:05 AMJazz Pharma announces expiration of HSR waiting period for Celator Pharma acquisition
06/24/16 07:21 AMPrice Target Update on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Trade Calls
06/23/16 05:05 PMStrong Buy Calls Count For Jazz Pharmaceuticals plc (NASDAQ:JAZZ) At 12 - Investor Newswire
06/23/16 07:39 AMFirst Week of August 19th Options Trading For Jazz Pharmaceuticals (JAZZ) - Nasdaq
06/23/16 07:39 AMJazz Pharmaceuticals Plc Ireland (NASDAQ:JAZZ) Sellers Covered 14.72% of Their Shorts - Press Telegraph
06/23/16 05:55 AMFive companies that could buy Ariad this year for as much as $2.9B -
06/22/16 09:25 AMWhat Do Gilead And Martin Shkreli Have In Common?
06/22/16 09:25 AMJazz Pharmaceuticals Presents New Data from Human Abuse Liability Study for JZP-110
06/21/16 04:27 PMFirst Week of August 19th Options Trading For Jazz Pharmaceuticals (JAZZ)
06/20/16 08:55 AMCompany Shares of Jazz Pharmaceuticals plc Drops by -4.73% - Trade Calls
06/20/16 06:34 AMJazz Pharmaceuticals PLC Conference Call to Discuss On JZP-110 Investor Update scheduled for 4:30 pm ET today -
06/19/16 04:17 PMThis Weeks Broker Views For Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) - Fiscal Standard
06/17/16 07:28 AMJazz Pharmaceuticals plc (NASDAQ:JAZZ) Accounts Payable Is $32.622 For The Quarter Ended 2016-03-31 - RealistInvestor.com
06/15/16 04:46 PMTrend Of Rating Given To Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Investor Newswire
06/15/16 04:46 PMJazz Pharmaceuticals Announces Conference Call and Webcast for JZP-110 Investor Update - PR Newswire (press release)
06/15/16 08:42 AMJazz Pharmaceuticals Offers HAL Study Data on JZP-110 -
06/14/16 04:35 PMJazz Pharmaceuticals to Present New Data on JZP-110 at SLEEP 2016
06/14/16 03:19 PMJazz Pharmaceuticals Announces Conference Call and Webcast for JZP-110 Investor Update - [at noodls] - DUBLIN, June 14, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it is hosting an investor conference call and audio webcast on Monday, June 20, 2016 at 4:30 p.m. EDT/9:30 ...
06/14/16 09:34 AMJazz Pharmaceuticals to Present New Data on JZP-110 at SLEEP 2016 - Sleep Review
06/14/16 09:34 AMGoldman Sachs Initiates Coverage on Jazz Pharmaceuticals plc - Ordinary Shares to Buy - TheFounders Daily
06/14/16 08:19 AMJazz Pharmaceuticals Presents New Data from a Human Abuse Liability (HAL) Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting - [at noodls] - DUBLIN, June 14, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced results from a Human Abuse Liability (HAL) study of JZP-110, an investigational wake-promoting agent in Phase ...
06/14/16 08:06 AM9:06 am Jazz Pharma to present new data from a Human Abuse Liability study of JZP-110 -
06/13/16 04:27 PMInvestor News: Investigation of Acquisition of Celator Pharmaceuticals Inc (NASDAQ:CPXX) announced
06/09/16 04:57 PMCan Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Meet Analysts Expectations? - Stocks Daily
06/09/16 07:27 AMSunTrust Robinson Humphrey Maintains Jazz Pharmaceuticals plc - Ordinary Shares to Buy with Price Target $210.00 - Trade Calls
06/08/16 07:30 AMJazz Pharmaceuticals plc (NASDAQ:JAZZ) went down -0.46%: PayPal Holdings, Inc. (NASDAQ:PYPL), Inventure ... - KC Register
06/07/16 04:54 PMJazz Pharmaceuticals plc - (JAZZ) Research Coverage Started at Goldman Sachs
06/07/16 07:18 AMGoldman Sees 26% Upside In Jazz Pharma Shares
06/06/16 04:39 PMGoldman Sees 26% Upside In Jazz Pharma Shares - Benzinga
06/06/16 07:56 AMJazz Pharma Started At Buy; Visa And Wal-Mart Upgraded -
06/04/16 07:30 AMJazz Pharmaceuticals plc (NASDAQ:JAZZ) Change In Inventory At $-7.63 Millions - RealistInvestor.com
06/03/16 05:04 PMJazz Pharmaceuticals plc Set to Expand After Celator Deal: Piper Jaffray - Bidness ETC
06/03/16 12:29 PMSarepta Therapeutics: Bears are 'Fundamentally Wrong.' Here's Why. -
06/03/16 07:27 AMPutnam Investments LLC Decreased Stake in Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) by $5.16 Million as Shares ... - CCH Daily News - Putnam Investments LLC Decreased Stake in Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) by $5.16 Million as Shares ...CCH Daily NewsPutnam Investments Llc decreased its stake in Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) by 0.38% based on its latest 2016Q1 regulatory filing with the SEC. Putnam Investments Llc sold 39,692 shares as the company's stock declined 4.89% while stock ...and more »
06/02/16 07:31 AMWestfield Capital Management Company LP Decreased Stake in Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) by $58.24 ... - CCH Daily News - Westfield Capital Management Company LP Decreased Stake in Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) by $58.24 ...CCH Daily NewsWestfield Capital Management Company Lp decreased its stake in Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) by 18.01% based on its latest 2016Q1 regulatory filing with the SEC. Westfield Capital Management Company Lp sold 447,999 shares as the ...and more »
06/02/16 07:31 AMJazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire ... - PR Newswire (press release) - Bidness ETCJazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire ...PR Newswire (press release)DUBLIN and EWING, N.J., May 31, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that they have entered into a definitive agreement for Jazz Pharmaceuticals to acquire ...Jazz Pharmaceuticals Agrees to Buy Celator for $1.5 BillionBloombergJazz Pharma to buy Celator in $1.5 billion dealReutersCelator Agrees to Jazz Pharmaceuticals' $1.5 Billion OfferBidness ETCMarketWatch -TickerTV News (press release)all 140 news articles »
06/01/16 05:03 PMBubbly Stocks in Focal Point- Great Plains Energy (NYSE:GXP), Jazz Pharmaceuticals Public (NASDAQ:JAZZ), Perrigo ... - Seneca Globe - Bubbly Stocks in Focal Point- Great Plains Energy (NYSE:GXP), Jazz Pharmaceuticals Public (NASDAQ:JAZZ), Perrigo ...Seneca GlobeJazz Pharmaceuticals Public Limited Firm (NASDAQ:JAZZ) knocked down -0.35% to finish at $151.56 in previous trading session. Bio-pharmaceutical firm Jazz Pharmaceuticals plc (JAZZ) stated that it would takeover oncology-focused bio-pharmaceutical ...Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) Jumped 71.59%: Westar Energy, Inc. (NYSE:WR), Medtronic plc ...KC RegisterDeals of the Day: Great Plains Nabs Westar, Jazz Lands CelatorWall Street Journal (blog)Notable Mergers and Acquisitions 5/31: (GXP)/(WR) (JAZZ)/(CPXX) (SQI) (MKTO)StreetInsider.comall 202 news articles »
06/01/16 12:17 PMYes, Biotech Unicorns Are Still Real -
06/01/16 07:32 AMStock Review and Earnings Check on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - HNN - Stock Review and Earnings Check on Jazz Pharmaceuticals plc (NASDAQ:JAZZ)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Jazz Pharmaceuticals plc ...and more »
06/01/16 07:32 AMJazz Pharmaceuticals agrees to buy Celator for $1.5 billion; US consumer confidence slips in May; Longtime Staples ... - Pittsburgh Post-Gazette - Pittsburgh Post-GazetteJazz Pharmaceuticals agrees to buy Celator for $1.5 billion; US consumer confidence slips in May; Longtime Staples ...Pittsburgh Post-GazetteJazz Pharmaceuticals Plc agreed to buy Celator Pharmaceuticals Inc. for about $1.5 billion to gain an experimental medicine for a rare blood cancer. Jazz, based in Dublin, offered $30.25 per share in cash for Ewing, New Jersey-based Celator. Celator's ...and more »
06/01/16 07:32 AMBRIEF-S&P-Jazz Pharmaceuticals Plc ratings affirmed on Celator acquisition plan outlook stable - Reuters - BRIEF-S&P-Jazz Pharmaceuticals Plc ratings affirmed on Celator acquisition plan outlook stableReutersMay 31 S&P. * Stable rating outlook reflects expectation that leverage will remain comfortably below 3x. * Jazz pharmaceuticals plc ratings affirmed on Celator acquisition plan; outlook stable. * Do not expect Celator to contribute meaningful sales and ...
06/01/16 06:30 AM[$$] Venture Investors in Celator Pharma Rewarded for Taking the Long View -
06/01/16 05:07 AMJAZZ PHARMACEUTICALS PLC Files SEC form 8-K/A, Regulation FD Disclosure, Financial Statements and Exhibits -
05/31/16 04:55 PMNoble Corp plc (NYSE:NE) went up 0.71%: Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ), KVH ... - KC Register - Noble Corp plc (NYSE:NE) went up 0.71%: Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ), KVH ...KC RegisterJazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) said that, it will present Goldman Sachs 37th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, June 8, 2016 at11:20 a.m. PDT / 7:20 p.m. IST. Russell Cox ...and more »
About Jazz Pharmaceuticals plc -

Jazz Pharmaceuticals plc - logoJazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: JAZZ
  • CUSIP: G5087110
Key Metrics:
  • Previous Close: $137.07
  • 50 Day Moving Average: $148.72
  • 200 Day Moving Average: $136.59
  • P/E Ratio: 25.86
  • P/E Growth: 0.64
  • Market Cap: $8.28B
  • Current Quarter EPS Consensus Estimate: $11.17 EPS
Additional Links:
Jazz Pharmaceuticals plc - (NASDAQ:JAZZ) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha